Gautier Paux

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5.

Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 18, 2024

Use of Seamless Study Designs in Oncology Clinical Development- A Survey Conducted by IDSWG Oncology Sub-team.

Use of Seamless Study Designs in Oncology Clinical Development- A Survey Conducted by IDSWG Oncology Sub-team.

Journal: Therapeutic innovation & regulatory science

Published: December 27, 2023

Reply to Y. Yoshitomi et al.

Reply to Y. Yoshitomi et al.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 30, 2023

AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.

AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 22, 2023

AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancer.

AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancer.

Journal: Breast cancer research : BCR

Published: April 04, 2023

Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation.

Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation.

Journal: Journal of the National Cancer Institute

Published: July 21, 2022

AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer.

AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer.

Journal: Nature communications

Published: June 18, 2021

Penalty-based approaches to evaluating multiplicity adjustments in clinical trials: Traditional multiplicity problems.

Penalty-based approaches to evaluating multiplicity adjustments in clinical trials: Traditional multiplicity problems.

Journal: Journal of biopharmaceutical statistics

Published: November 28, 2017

Penalty-based approaches to evaluating multiplicity adjustments in clinical trials: Advanced multiplicity problems.

Penalty-based approaches to evaluating multiplicity adjustments in clinical trials: Advanced multiplicity problems.

Journal: Journal of biopharmaceutical statistics

Published: November 11, 2017

Tradeoff-based optimization criteria in clinical trials with multiple objectives and adaptive designs.

Tradeoff-based optimization criteria in clinical trials with multiple objectives and adaptive designs.

Journal: Journal of biopharmaceutical statistics

Published: September 23, 2015

Implementation of adaptive methods in early-phase clinical trials.

Implementation of adaptive methods in early-phase clinical trials.

Journal: Statistics in medicine

Published: August 03, 2015

Showing 1-11 of 11

Last Updated: 09/26/2026